Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adavosertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 known ✓ | P30291 | 20/20 | 1.00 |
| ▸ | PLK1 | P53350 | 6/20 | 1.00 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | WEE2 | P0C1S8 | 1/20 | 1.00 |
| ▸ | BCR | P11274 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | SYK | P43405 | 1/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 1.00 |
| ▸ | NEK2 | P51955 | 1/20 | 1.00 |
| ▸ | NEK3 | P51956 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adavosertib SCHEMBL29381006 | 1.00 | WEE1 (1.00) | WEE1PLK1PKMYT1GAKEPHB6 | |
| Adavosertib SCHEMBL30559444 | 1.00 | WEE1 (1.00) | WEE1PLK1PKMYT1GAKEPHB6 | |
| Adavosertib SCHEMBL1504996 | 0.99 | WEE1 (0.98) | WEE1PLK1PKMYT1GAKEPHB6 | |
| Adavosertib SCHEMBL1504998 | 0.99 | WEE1 (0.98) | WEE1PLK1PKMYT1GAKEPHB6 | |
| SCHEMBL25890930 | 0.98 | WEE1 (0.96) | WEE1PLK1PKMYT1GAKEPHB6 | |
| SCHEMBL1815951 | 0.97 | WEE1 (0.94) | WEE1PLK1PKMYT1GAKEPHB6 | |
| Adavosertib SCHEMBL3579242 | 0.97 | WEE1 (0.94) | WEE1PLK1PKMYT1GAKEPHB6 | |
| SCHEMBL1811019 | 0.94 | WEE1 (0.89) | WEE1PLK1PKMYT1GAKEPHB6 | |
| SCHEMBL1813967 | 0.94 | WEE1 (0.89) | WEE1PLK1PKMYT1GAKEPHB6 | |
| SCHEMBL15959140 | 0.94 | WEE1 (0.89) | WEE1PLK1PKMYT1GAKEPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2042 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-26 | — | — | US | claimed |
| WO-2026104998-A1 | SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2026-05-21 | — | — | WO | claimed |
| WO-2025217307-A9 | METHODS FOR PREDICTING RESPONSE TO A RAS(ON) INHIBITOR AND COMBINATION THERAPIES | Revolution Medicines, Inc. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4735448-A1 | SUBSTITUTED SPIRO COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-05-06 | — | — | EP | claimed |
| US-20260092327-A1 | METHODS OF MONITORING MUTATIONS IN TREATMENT OF COLORECTAL CANCER | CARDIFF ONCOLOGY INC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260076970-A1 | CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY INC (US) | 2026-03-19 | — | — | US | claimed |
| EP-3850004-B1 | NATURAL KILLER CELL COMPOSITIONS AND IMMUNOTHERAPY METHODS FOR TREATING A LIVER TUMOR | NKARTA INC (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4688775-A1 | SUBSTITUTED SULTAM COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-02-11 | — | — | EP | claimed |
| US-20260009798-A1 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR | ACRIVON THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | claimed |
| US-20250387643-A1 | METHODS AND APPARATUS FOR APPLYING TUMOR TREATING FIELDS COMBINED WITH PERSONALIZED ULTRA-FRACTIONATED STEREOTACTIC ADAPTIVE RADIOTHERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-12-25 | — | — | US | claimed |
| WO-2010076887-A1 | PREDICTIVE BIOMARKERS USEFUL FOR CANCER THERAPY MEDIATED BY A WEE1 INHIBITOR | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-07-08 | — | — | WO | claimed |
| US-20100124544-A1 | CRYSTALLINE FORMS OF DIHYDROPYRAZOLOPYRIMIDINONE | MERCK & CO., INC. | 2010-05-20 | — | — | US | claimed |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | MERCK SHARP & DOHME LLC | 2010-03-11 | — | — | US | claimed |
| EP-2155752-A1 | POLYMORPH OF DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE AS WEEL KINASE.INHIBITOR | Merck & Co., Inc. (US) | 2010-02-24 | — | — | EP | claimed |
| EP-2016080-A4 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2009-05-13 | — | — | EP | claimed |
| EP-2016080-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | claimed |
| EP-2017278-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | claimed |
| WO-2008133866-A1 | POLYMORPH OF DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE AS WEEL KINASE.INHIBITOR | MERCK & CO., INC. (US) | 2008-11-06 | — | — | WO | claimed |
| WO-2007126122-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-11-08 | — | — | WO | claimed |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2007-11-01 | — | — | US | claimed |